Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology recommended by NICE. These cookies remember information that ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. These cookies remember ...

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative devices and digital therapeutics transform patient care as ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

you can comment on draft recommendations the final recommendations are published published guidance is being reviewed. We'll use the information you provide on this form to contact you about the ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

Somapacitan (Sogroya, Novo Nordisk) is indicated 'for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone ...

Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company ...